http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0582630-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C281-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C281-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
filingDate 1992-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46562b79a8b790c5fa47db5287e0a476
publicationDate 1994-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0582630-A4
titleOfInvention N?6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
abstract Physiologically active N6-(hydrazinoiminomethyl)lysine or pharmaceutically acceptable acid addition salt thereof is administered in a nitric oxide sythesis inhibiting amount to a subject in need of such inhibition (e.g., a subject with low blood pressure, e.g., due to sepsis or to therapeutic administration of cytokines, or needing immunosuppressive effect) or is added to a medium containing isolated organs, intact cells, cell homogenates or tissue homogenates in an amount sufficient to inhibit nitric oxide formation to elucide or control the biosynthesis, metabolism or physiological role of nitric oxide. Compared to known nitric oxide synthesis inhibitors, N6-(hydrazinoiminomethyl)lysine and its acid addition salts show a greater relative activity toward inducible isoform of nitric oxide synthase than toward constitutive isoform of nitric oxide synthase. N6-(hydrazinoiminomethyl)lysine and its pharmaceutically acceptable acid addition salts are substantially less toxic than are NG-amionoarginine and its pharmaceutically acceptable acid addition salts.
priorityDate 1991-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0446699-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88442226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234148956
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234715606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396655
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87603953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234714848
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396654
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88341236
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234714841
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1318
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234145458
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID232705342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234714836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234145420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88341250
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88442230
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69568
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88442229
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420053
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88442340
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18392145
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4782
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19693929
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9085
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22845053
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234148917
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10226
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22845054
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234148916
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22845052
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4737
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393853
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3626
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427748
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399547
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234147546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88341249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234147542
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88340555
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229942728
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19920011
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88340969
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226471056
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19920010
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229942118
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226426718
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413167
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234148963
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73046
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID229942114
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID234148961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4807
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226471257
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395454

Total number of triples: 79.